Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025
April 29, 2025 20:53 ET | Source: Mesoblast Limited NEW YORK, April…
Ryoncil is Now Available for Purchase in the United States
March 26, 2025 20:19 ET | Source: Mesoblast Limited NEW YORK, March…
Mesoblast Added to S&P/ASX 200 INDEX
March 06, 2025 18:54 ET | Source: Mesoblast Limited NEW YORK, March…
Dr. Gregory George MD PhD Joins Mesoblast Board
February 23, 2025 18:33 ET | Source: Mesoblast Limited NEW YORK, Feb.…
Mesoblasts RYONCIL is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
December 18, 2024 19:08 ET | Source: Mesoblast Limited RYONCIL (remestemcel-L) is…
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
Phase 3 trial results published in European Journal of Heart Failure identify…